Optimizing ART With Novel HIV Agents

CCO Infectious Disease Podcast

Nội dung được cung cấp bởi Clinical Care Options, LLC and Clinical Care Options. Tất cả nội dung podcast bao gồm các tập, đồ họa và mô tả podcast đều được Clinical Care Options, LLC and Clinical Care Options hoặc đối tác nền tảng podcast của họ tải lên và cung cấp trực tiếp. Nếu bạn cho rằng ai đó đang sử dụng tác phẩm có bản quyền của bạn mà không có sự cho phép của bạn, bạn có thể làm theo quy trình được nêu ở đây https://vi.player.fm/legal.

27d ago 12:32

MP3•Trang chủ episode

In this episode, Gregory Huhn, MD, MPHTM, presents a case study of a person with a long HIV treatment history, exploring when and how to consider agents with novel mechanisms of action.

Listen as he discusses:

The importance of engaging with patients to understand their perspectives and improve their satisfaction with their HIV care
Options in people with multiclass resistance
Studies of agents with novel mechanisms of action:
- BRIGHTE (fostemsavir)
- TMB-301/-311 (ibalizumab)
- CAPELLA (lenacapavir)

Faculty

Gregory Huhn, MD, MPHTM,
Interim Chief, Division of Infectious Diseases
Senior Director of HIV Services
Cook County HIV Integrated Programs
Interim Medical Director, The RMR CORE Center
Professor, Division of Infectious Diseases
Rush University Medical Center
Chicago, Illinois

Follow along with the slides.
https://bit.ly/4fHmxg5

Get access to all of our new podcast episodes. Subscribe to the CCO Infectious Disease podcast on Apple Podcasts, Google Podcasts, or Spotify.

406 tập

#Science #Fitness #Biology #Higher Education #Podcasting Education #Medicine #Clinical Care Options, LLC #Clinical Care Options #HIV #On Covid19 #CME #Hepatitis B #Hbv #Infectious Disease Medical Education #Id Medical Education #Coronavirus #Hepatitis C #Hcv